Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of the investigational antibiotic SIVEXTRO
(tedizolid phosphate) for the treatment of acute bacterial skin and skin
structure infections (ABSSSI) in adults. Merck acquired SIVEXTRO as a
part of its purchase, through a subsidiary, of Cubist Pharmaceuticals,
Inc.
Language:
English
Contact:
Media:Pam Eisele, 267-305-3558Jennifer Baird, 781-860-1282orInvestor:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more